Gloria B. Chiu, OD, FAAO, FSLS

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Chiu discusses factors affecting adoption of the FDA-approved epi-on therapy, from clinic setup to insurance coverage, while highlighting its safety and efficacy.

Equally important is that any symptoms of ocular allergies should be addressed to reduce the frequency of eye rubbing.